The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues

Journal of Medicinal Chemistry

Volumn 52, Issue 18, 2009, Pages 5612-5618

  Lukaszuk, Aneta ^a   Demaegdt, Heidi ^a   Feytens, Debby ^a   Vanderheyden, Patrick ^a   Vauquelin, Georges ^a   Tourwé, Dirk ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II [3-8]; ANGIOTENSIN RECEPTOR; BETA2 HOMOAMINOVALYLTYROSYLISOLEUCINE 4 AMINO 1,2,4,5 TETRAHYDROINDOLO[2,3 C]AZEPIN ONE GLYCYLPHENYLALANINE; DIPEPTIDE; HEXAPEPTIDE; HISTIDINE; INSULIN REGULATED AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; PROLINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; NONHUMAN;

AMINO ACID SEQUENCE; AMINOPEPTIDASES; ANGIOTENSIN II; ANIMALS; AZEPINES; BIOMIMETICS; CARBOXYLIC ACIDS; CHO CELLS; CRICETINAE; CRICETULUS; CYSTINYL AMINOPEPTIDASE; HISTIDINE; HUMANS; PHENYLALANINE; PROTEIN CONFORMATION; RECEPTOR, ANGIOTENSIN, TYPE 1; SUBSTRATE SPECIFICITY;

EID: 70349200782     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900651p     Document Type: Article

References (56)

1. de Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52, 415-472.
2. Gasparo de, M.; Husain, A.; Alexander, W.; Catt, K. J.; Chiu, A. T.; Drew, M.; Goodfriend, T.; Harding, J. W.; Inagami, T.; Timmermans, P. B. Proposed update of angiotensin receptor nomenclature. Hypertension 1995, 25, 924-927.
3. Swanson, G. N.; Hanesworth, J. M.; Sardinia, M. F.; Coleman, J. K.; Wright, J. W.; Hall, K. L.; Miller-Wing, A. V.; Stobb, J. W.; Cook, V. I.; Harding, E. C.; et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul. Pept. 1992, 40, 409-419.
4. Chai, S. Y.; Fernando, R.; Peck, G.; Ye, S. Y.; Mendelsohn, F. A.; Jenkins, T. A.; Albiston, A. L. The angiotensin IV/AT4 receptor. Cell. Mol. Life. Sci. 2004, 61, 2728-2737.
5. Albiston, A. L.; McDowall, S. G.; Matsacos, D.; Sim, P.; Clune, E.; Mustafa, T.; Lee, J.; Mendelsohn, F. A.; Simpson, R. J.; Connolly, L. M.; Chai, S. Y. Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001, 276, 48623-48626.
6. Rogi, T.; Tsujimoto, M.; Nakazato, H.; Mizutani, S.; Tomoda, Y. Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. J. Biol. Chem. 1996, 271, 56-61.
7. Delorenzi, A.; Locatelli, F.; Romano, A.; Nahmod, V.; Maldonado, H. Angiotensin II (3-8) induces long-term memory improvement in the crab Chasmagnathus. Neurosci. Lett. 1997, 226, 143-146.
8. Wallis, M. G.; Lankford, M. F.; Keller, S. R. Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E1092-E1102.
9. Stragier, B.; De Bundel, D.; Sarre, S.; Smolders, I.; Vauquelin, G.; Dupont, A.; Michotte, Y.; Vanderheyden, P. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Failure Rev. 2008, 13, 321-337.
10. Wright, J. W.; Krebs, L. T.; Stobb, J. W.; Harding, J. W. The angiotensin IV system: functional implications. Front. Neuroendocrinol. 1995, 16, 23-52.
11. Lew, R. A.; Mustafa, T.; Ye, S.; McDowall, S. G.; Chai, S. Y.; Albiston, A. L. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J. Neurochem. 2003, 86, 344-350.
12. Albiston, A. L.; Mustafa, T.; McDowall, S. G.; Mendelsohn, F. A.; Lee, J.; Chai, S. Y. AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. Trends Endocrinol. Metab. 2003, 14, 72-77.
13. Keller, S. R.; Scott, H. M.; Mastick, C. C.; Aebersold, R.; Lienhard, G. E. Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J. Biol. Chem. 1995, 270, 23612-23618.
14. Vauquelin, G.; Michotte, Y.; Smolders, I.; Sarre, S.; Ebinger, G.; Dupont, A.; Vanderheyden, P. Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J. Renin Angiotensin Aldosterone Syst. 2002, 3, 195-204.
15. Wright, J. W.; Harding, J. W. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog. Neurobiol. 2004, 72, 263-293.
16. Garreau, I.; Chansel, D.; Vandermeersch, S.; Fruitier, I.; Piot, J. M.; Ardaillou, R. Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 1998, 19, 1339-1348. (Pubitemid 28514438)
17. Lukaszuk, A.; Demaegdt, H.; Szemenyei, E.; Toth, G.; Tymecka, D.; Misicka, A.; Karoyan, P.; Vanderheyden, P.; Vauquelin, G.; Tourwe, D. Beta-homo-amino acid scan of angiotensin IV. J. Med. Chem. 2008, 51, 2291-2296.
18. Lelais, G.; Seebach, D. Beta2-amino acids syntheses, occurrence in natural products, and components of beta-peptides. Biopolymers 2004, 76, 206-243.
19. Ondetti, M. A.; Engel, S. L. Bradykinin analogs containing beta-homoamino acids. J. Med. Chem. 1975, 18, 761-763.
20. Steer, D. L.; Lew, R. A.; Perlmutter, P.; Smith, A. I.; Aguilar, M. I. Beta-amino acids: versatile peptidomimetics. Curr. Med. Chem. 2002, 9, 811-822.
21. Frackenpohl, J.; Arvidsson, P. I.; Schreiber, J. V.; Seebach, D. The outstanding biological stability of beta- and gamma-peptides toward proteolytic enzymes: an in vitro investigation with fifteen peptidases. ChemBioChem. 2001, 2, 445-455. (Pubitemid 33723576)
22. Zubrzak, P.; Williams, H.; Coast, G. M.; Isaac, R. E.; Reyes-Rangel, G.; Juaristi, E.; Zabrocki, J.; Nachman, R. J. Beta-amino acid analogs of an insect neuropeptide feature potent bioactivity and resistance to peptidase hydrolysis. Biopolymers 2007, 88, 76-82.
23. Hook, D. F.; Bindschadler, P.; Mahajan, Y. R.; Sebesta, R.; Kast, P.; Seebach, D. The proteolytic stability of "designed" beta-peptides containing alpha-peptide-bond mimics and of mixed alpha, beta-peptides: Application to the construction of MHC-binding peptides. Chem. Biodiversity 2005, 2, 591-632.
24. Seebach, D.; Overhand, M.; Kuhnle, F. N. M.; Martinoni, B.; Oberer, L.; Hommel, U.; Widmer, H. β-peptides: Synthesis by Arndt-Eistert homologation with concomitant peptide coupling. Structure determination by NMR and CD spectroscopy and by X-ray crystallography. Helical secondary structure of a beta-hexapeptide in solution and its stability towards pepsin. Helv. Chim. Acta 1996, 79, 913-941.
25. Seebach, D.; Gardiner, J. β-Peptidic peptidomimetics. Acc. Chem. Res. 2008, 41, 1366-1375.
26. 3- Tetrapeptide Derivatives with Nanomolar Affinities to a Human Somatostatin Receptor. Helv. Chim. Acta 2001, 84, 3503-3510.
27. Hook, D. F.; Gessier, F.; Noti, C.; Kast, P.; Seebach, D. Probing the Proteolytic Stability of β-Peptides Containing α-Fluoro- and α-Hydroxy-β-Amino Acids. ChemBioChem. 2004, 5, 691-706. (Pubitemid 39257092)
28. Seebach, D.; Abele, S.; Schreiber, J. V.; Martinoni, B.; Nussbaum, A. K.; Schild, H.; Schulz, H.; Hennecke, H.; Woessner, R.; Bitsch, F. Biological and Pharmacokinetic Studies with β-Peptides. Chimia 1998, 52, 734-739.
29. Heck, T.; Limbach, M.; Geueke, B.; Zacharias, M.; Gardiner, J.; Kohler, H.-P. E.; Seebach, D. Enzymatic Degradation of β- and Mixed α,β-Oligopeptides. Chem. Biodiversity 2006, 3, 1325-1348.
30. Geueke, B.; Kohler, H. P. Bacterial beta-peptidyl aminopeptidases: on the hydrolytic degradation of beta-peptides. Appl. Microbiol. Biotechnol. 2007, 74, 1197-1204.
31. 2-Homoserine for Solid-Phase Syntheses. Helv. Chim. Acta 2004, 87, 3131-3159.
32. Cowell, S. M.; Lee, Y. S.; Cain, J. P.; Hruby, V. J. Exploring Ramachandran and chi space: conformationally constrained amino acids and peptides in the design of bioactive polypeptide ligands. Curr. Med. Chem. 2004, 11, 2785-2798.
33. Hruby, V. J.; Balse, P. M. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem. 2000, 7, 945-970.
34. Hruby, V. J. Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind-body problem. Acc. Chem. Res. 2001, 34, 389-397.
35. Gibson, S. E.; Guillo, N.; Tozer, M. J. Towards control of c-space: Conformationally constrained analogues of Phe, Tyr, Trp and His. Tetrahedron 1999, 55, 585-615.
36. Tourwe, D.; Verschueren, K.; Frycia, A.; Davis, P.; Porreca, F.; Hruby, V. J.; Toth, G.; Jaspers, H.; Verheyden, P.; Van, B. G. Conformational restriction of Tyr and Phe side chains in opioid peptides: information about preferred and bioactive side-chain topology. Biopolymers 1996, 38, 1-12. (Pubitemid 26004808)
37. Kazmierski, W.; Hruby, V. J. A new approach to receptor ligand design: synthesis and conformation of a new class of potent and highly selective [mu] opioid antagonists utilizing tetrahydroisoquinoline carboxylic acid. Tetrahedron 1988, 44, 697-710.
38. Sánchez-Sánchez, M. M.; Tel-Alberdi, L. M.; Rioseras, M. J.; Rico-Ferreira, M. R.; Bermejo-González, F. The Pictet-Spengler Reaction on L-Histidine. Preparation of Conformationally Restricted (+)-Pilocarpine Analogs. Bull. Chem. Soc. Jpn. 1993, 66, 191-195.
39. Kazmierski, W. M.; Yamamura, H. I.; Hruby, V. J. Topographic Design of Peptide Neurotransmitters and Hormones on Stable Backbone Templates - Relation of Conformation and Dynamics to Bioactivity. J. Am. Chem. Soc. 1991, 113, 2275-2283.
40. Ballet, S.; Mayorov, A. V.; Cai, M.; Tymecka, D.; Chandler, K. B.; Palmer, E. S.; Rompaey, K. V.; Misicka, A.; Tourwe, D.; Hruby, V. J. Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5- tetrahydro-2-benzazepin-3-one (Aba) scaffold. Bioorg. Med. Chem. Lett. 2007, 17, 2492-2498.
41. Pulka, K.; Feytens, D.; Van den Eynde, I.; De Wachter, R.; Kosson, P.; Misicka, A.; Lipkowski, A.; Chung, N. N.; Schiller, P. W.; Tourwe, D. Synthesis of 4-amino-3-oxo-tetrahydroazepino-[3,4-b]indoles: new conformationally constrained Trp analogs. Tetrahedron 2007, 63, 1459-1466.
42. Kyle, D. J.; Martin, J. A.; Farmer, S. G.; Burch, R. M. Design and conformational analysis of several highly potent bradykinin receptor antagonists. J. Med. Chem. 1991, 34, 1230-1233.
43. Schiller, P. W.; Weltrowska, G.; Berezowska, I.; Nguyen, T. M.; Wilkes, B. C.; Lemieux, C.; Chung, N. N. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers 1999, 51, 411-425.
44. Casimir, J. R.; Iterbeke, K.; Van Den, N. W.; Trescol-Biemont, M. C.; Dumortier, H.; Muller, S.; Gerlier, D.; Rabourdin-Combe, C.; Tourwe, D.; Paris, J. Conformational restriction of the Tyr53 sidechain in the decapeptide HE. J. Pept. Res. 2000, 56, 398-408.
45. Ballet, S.; Frycia, A.; Piron, J.; Chung, N. N.; Schiller, P. W.; Kosson, P.; Lipkowski, A. W.; Tourwe, D. Synthesis and biological evaluation of constrained analogues of the opioid peptide H-Tyr-D-Ala-Phe-Gly-NH2 using the 4-amino-2-benzazepin-3-one scaffold. J. Pept. Res. 2005, 66, 222-230.
46. Hintermann, T.; Seebach, D. A useful modification of the Evans auxiliary: 4-isopropyl-5,5-diphenyloxazolidin-2-one. Helv. Chim. Acta 1998, 81, 2093-2126.
47. Seebach, D.; Beck, A. K.; Capone, S.; Deniau, G.; Groselj, U.; Zass, E. Enantioselective Preparation of β-Amino Acid Derivatives for β-Peptide Synthesis. Synthesis 2009, 2009, 1-32.
48. 125I]Ang IV binding and catalytic activity. Biochem. Pharmacol. 2004, 68, 885-892.
49. 125I]angiotensin IV only binds to the cystinyl aminopeptidase apoenzyme. Eur. J. Pharmacol. 2006, 546, 19-27.
50. Irons, D. W.; Davison, J. M.; Baylis, P. H. Evaluation of enzyme inhibitors of cystinyl aminopeptidase and application to the measurement of immunoreactive atrial natriuretic peptide in human pregnancy. Clin. Chim. Acta 1994, 231, 185-191.
51. Sardinia, M. F.; Hanesworth, J. M.; Krishnan, F.; Harding, J. W. AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 1994, 15, 1399-1406.
52. Axen, A.; Andersson, H.; Lindeberg, G.; Ronnholm, H.; Kortesmaa, J.; Demaegdt, H.; Vauquelin, G.; Karlen, A.; Hallberg, M. Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor. J. Pept. Sci. 2007, 13, 434-444.
53. Demaegdt, H.; Lukaszuk, A.; Buyser, E. D.; Backer, J.-P. D.; Szemenyei, E.; Tóth, G.; Chakravarthy, S.; Panicker, M.; Michotte, Y.; Tourwé, D.; Vauquelin, G. Selective labelling of IRAP by the tritiated AT4 receptor ligands [3H]Angiotensin IV and its stable analog [3H]AL-11. 2009, submitted for publication .
54. Olsen, J.; Cowell, G. M.; Konigshofer, E.; Danielsen, E. M.; Moller, J.; Laustsen, L.; Hansen, O. C.; Welinder, K. G.; Engberg, J.; Hunziker, W.; et al. Complete amino acid sequence of human intestinal aminopeptidaseNas deduced from cloned cDNA. FEBS Lett. 1988, 238, 307-314. (Pubitemid 18244939)
55. Vanderheyden, P. M. L.; Fierens, F. L. P.; De Backer, J. P.; Fraeyman, N.; Vauquelin, G. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. Br. J. Pharmacol. 1999, 126, 1057-1065.
56. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.